title: Effects of permanent pacemaker and oral theophylline in sick sinus syndrome the THEOPACE study: a randomized controlled trial.
abstract: BACKGROUND
  Pacemakers and theophylline are currently being used to relieve symptoms in patients with sick sinus syndrome (SSS). However, the impact of either therapy on the natural course of the disease is unknown. We conducted a randomized controlled trial to prospectively assess the effects of pacemakers and theophylline in patients with SSS.
  
  
  RESULTS
  One hundred seven patients with symptomatic SSS (age, 73 +/- 11 years) were randomized to no treatment (control group, n = 35), oral theophylline (n = 36), or dual-chamber rate-responsive pacemaker therapy (n = 36). They were followed for up to 48 months (mean, 19 +/- 14 months). During follow-up, the occurrence of syncope was lower in the pacemaker group than in the control group (P = .02) and tended to be lower than in the theophylline group (P = .07). Heart failure occurred less often in patients assigned to pacemaker therapy and theophylline than in control patients (both, P = .05), whereas the incidence of sustained paroxysmal tachyarrhythmias, permanent atrial fibrillation, and thromboembolic events did not show any apparent difference among the three groups. Heart rate was higher in the theophylline group than in the control group. Both pacemaker therapy and theophylline improved symptom scores after 3 months of treatment; however, a similar improvement was observed in the control group.
  
  
  CONCLUSIONS
  In patients with symptomatic SSS, therapy with theophylline or dual-chamber pacemaker is associated with a lower incidence of heart failure; pacemaker therapy is also associated with a lower incidence of syncope. The therapeutic benefits of pacemakers and theophylline on symptoms are partly a result of spontaneous improvement of the disease.
authors.affiliation: Division of Cardiology, Ospedale Civile, Cento, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Alboni
authors.forename: C
authors.initials: C
authors.lastname: Menozzi
authors.forename: M
authors.initials: M
authors.lastname: Brignole
authors.forename: N
authors.initials: N
authors.lastname: Paparella
authors.forename: G
authors.initials: G
authors.lastname: Gaggioli
authors.forename: G
authors.initials: G
authors.lastname: Lolli
authors.forename: R
authors.initials: R
authors.lastname: Cappato
mesh_terms: D000284:Administration, Oral; D000368:Aged; D001281:Atrial Fibrillation / Q000453:epidemiology; D002303:Cardiac Output, Low / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D010138:Pacemaker, Artificial; D011446:Prospective Studies; D012804:Sick Sinus Syndrome / Q000097:blood / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D013575:Syncope / Q000453:epidemiology; D013614:Tachycardia, Paroxysmal / Q000453:epidemiology; D013806:Theophylline / Q000008:administration & dosage* / Q000097:blood; D013923:Thromboembolism / Q000209:etiology
chemical_list: D013806:Theophylline